Cognition Therapeutics (CGTX) Insider Trading & Ownership $0.37 -0.01 (-2.64%) As of 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cognition Therapeutics (NASDAQ:CGTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage20.75%Number OfInsiders Buying(Last 3 Years)3Amount OfInsider Buying(Last 3 Years)$67,075.00Number OfInsiders Selling(Last 3 Years)0 Get CGTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Cognition Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CGTX Insider Buying and Selling by Quarter Remove Ads Cognition Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/14/2024Lisa RicciardiCEOBuy5,700$1.75$9,975.00 11/29/2022Ellen B RichstoneDirectorBuy10,000$2.65$26,500.00 11/15/2022Lisa RicciardiCEOBuy12,000$1.30$15,600.00 11/15/2022Peggy WallaceDirectorBuy12,500$1.20$15,000.00 (Data available from 1/1/2013 forward) CGTX Insider Trading Activity - Frequently Asked Questions Who is on Cognition Therapeutics's Insider Roster? The list of insiders at Cognition Therapeutics includes Ellen B Richstone, Lisa Ricciardi, and Peggy Wallace. Learn more on insiders at CGTX. What percentage of Cognition Therapeutics stock is owned by insiders? 20.75% of Cognition Therapeutics stock is owned by insiders. Learn more on CGTX's insider holdings. Which Cognition Therapeutics insiders have been buying company stock? The following insider purchased CGTX shares in the last 24 months: Lisa Ricciardi ($9,975.00). How much insider buying is happening at Cognition Therapeutics? Insiders have purchased a total of 5,700 CGTX shares in the last 24 months for a total of $9,975.00 bought. Cognition Therapeutics Key ExecutivesMs. Lisa Ricciardi (Age 64)CEO, President & Director Compensation: $854.15kMr. John Brendan Doyle (Age 47)Chief Financial Officer Compensation: $414.88kDr. Anthony O. Caggiano M.D. (Age 54)Ph.D., Chief Medical Officer and Head of R&D Compensation: $616.27kDr. Steven A. Weissman Ph.D.VP & Head of CMC More Insider Trading Tools from MarketBeat Related Companies Oramed Pharmaceuticals Insider Buying Immunic Insider Buying Climb Bio Insider Buying Galectin Therapeutics Insider Buying Atossa Therapeutics Insider Buying Zentalis Pharmaceuticals Insider Buying Editas Medicine Insider Buying Neoleukin Therapeutics Insider Buying Kyverna Therapeutics Insider Buying Virios Therapeutics Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Beware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldJoby Aviation: Operational Momentum vs. Market SentimentMicroStrategy Sees Insider Buy-Sell Action in Q1 This page (NASDAQ:CGTX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CGTX Stock Free CGTX Stock Alerts